Eagle Pharmaceuticals Inc (EGRX) — Cash Flow Quality Index

Latest as of June 2023: -0.02x

Eagle Pharmaceuticals Inc (EGRX) has a Cash Flow Quality Index of -0.02x as of June 2023. Operating cash flow of $-126.00K is below net income of $5.16 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore EGRX operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

-0.02x
Operating CF / Net Income

Operating Cash Flow

$-126.00K
USD

Net Income

$5.16 Million
USD

Data as of

Jun 2023
Most recent filing

Eagle Pharmaceuticals Inc Cash Flow Quality Index (2015–2020)

Historical Cash Flow Quality Index for Eagle Pharmaceuticals Inc across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Eagle Pharmaceuticals Inc operating cash flow efficiency.

Annual Cash Flow Quality Index for Eagle Pharmaceuticals Inc (2015–2020)

Year-by-year earnings quality comparison for Eagle Pharmaceuticals Inc.

Year Quality Index Operating CF (USD) Net Income YoY Change
2020 4.13x $49.50 Million $11.99 Million ▲ +5.5%
2019 3.91x $55.99 Million $14.31 Million ▲ +138.2%
2018 1.64x $52.38 Million $31.90 Million ▲ +44.8%
2017 1.13x $58.92 Million $51.94 Million ▲ +73.6%
2016 0.65x $53.21 Million $81.45 Million ▲ +117.3%
2015 -3.78x $-9.72 Million $2.57 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.